Navigation Links
Study shows AIDS drugs cost-effective, care underfunded

the board: the inadequacy of reimbursement to the treating physicians and clinics.

In the study, medications were the single costliest component, comprising $71 to $84 of every $100 spent, regardless of stage of disease. In sharp contrast, expenditures for physicians' services and clinic fees accounted for less than $2 of every $100, or on average, $360 per patient per year. This is far less than the providers' actual costs, which average approximately $1,500 to 2,000 per patient per year. The study assumed all patients had Medicare health insurance and the clinics were reimbursed 100 percent. "However, the majority of people who are infected with HIV are either uninsured or underinsured" and unable to pay for their care, said Dr. Saag. "So in reality, the actual reimbursement to clinics is markedly less than $360 per patient per year, making the situation even more dire," he added.

As a consequence, said Dr. Saag, "We are approaching a potential crisis in the availability of physicians to provide care for patients? Many private-practice HIV clinics are closing. Most academic institutions within the United States, including ours, are absorbing the cost of care for HIV patients" ?a burden that can range into the millions of dollars, he said. These treatment providers' necessary reliance on federal assistance "underscores the tremendous need for reauthorization of the Ryan White CARE Act with increased resources allocated for reimbursement of medical care, which is now under discussion in Congress," Dr. Saag said.

Although institutions are developing ways to bring down HIV treatment costs, they won't be able to cover those costs themselves indefinitely, Dr. Saag warned. Notwithstanding the promising findings on HAART's cost-effectiveness, "Providing drugs alone is not enough," he said. "We must focus now on creating appropriate incentives for providers to care for HIV patients. The current pool of providers is struggling to make ends meet.
'"/>

Source:Infectious Diseases Society of America


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study shows AIDS drugs cost effective care underfunded

(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... to hear relies on hair cells, sensory receptors that mechanically ... transduction channel. Although the transduction channel was characterized more than ... molecular components. A new study in The Journal ... definitive identification of this mystery channel. Recent studies ...
... a long and complex process. Candidate drugs are evaluated ... of animals, usually rats or mice. Each class of ... often in a labor-intensive process that leaves plenty of ... consensus that current procedures fail to effectively produce new ...
... Clinical Practice Guideline (CPG) for the diagnosis and treatment ... in women of reproductive age and a leading cause ... of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice ... the Journal of Clinical Endocrinology and Metabolism ...
Cached Biology News:Finding psychiatric drugs in the movements of mice 2Finding psychiatric drugs in the movements of mice 3Experts clarify conflicting criteria for diagnosing polycystic ovary syndrome 2
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is ... of partially hydrolyzed gluten in foods, has been accepted by AOAC International as ... Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a ...
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... DIEGO, July 30, 2015   Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... industries, today reported financial results for the second quarter ... of 2015, we remain on track to achieve our ... Chief Executive Officer of the Company. "Since our last ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... 2011 Reportlinker.com announces that a ... in its catalogue: What,s ... and Other Biologics) 2011-2015 ... future of the pharmaceutical market will ...
... aid the fight of the deadly outbreak of E. ... at the University Medical Centre Hamburg-Eppendorf have released an ... data previously released and submitted to NCBI in the ... assembled using the latest ion semiconductor sequencing technology, there ...
... Asmacure Ltee, a clinical-stage biopharmaceutical company focused ... treatment of asthma and other inflammatory diseases, announced today ... officer.  With a solid foundation established at Asmacure, Mr. ... lead compound, a potential new treatment for asthma with ...
Cached Biology Technology:Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 2Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 3Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 4Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 5Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 6Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 7Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 2Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 3Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
Biology Products: